Wealthforge, a provider of investment crowdfunding services, has joined with Gar Wood Securities on Histogen‘s series D funding round. Wealth forge will serve as lead placement in the $18 million raise.
This round will provide capital for development of its HSC program, including a US Phase I clinical trial in female diffuse hair loss patients and a late-stage HSC trial in male pattern hair loss, expand its manufacturing capability, other corporate purposes and to support preparation for an initial public offering (IPO). The company has raised $27 million since its creation in 2007.
Arthur Weissman, Head of Sales and Marketing at Wealthforge commented on the funding round.
“At WealthForge, our mission is simple – to lower costs throughout the entire private placement process. We’re proud to work with a partner like Histogen to help them scale their business by making the process of raising private capital faster and more compliant than ever before.”
Histogen is a medtech company that is developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation.
In May 2015, Histogen opened its Series D financing round to support clinical development of its Hair Stimulating Complex (HSC), including a US Phase I clinical trial in female diffuse hair loss patients and a late-stage HSC trial in male pattern hair loss, expand its manufacturing capability, and to support preparation for an initial public offering (IPO).
“Histogen is pleased to partner with WealthForge on this financing raise,” said Dr. Gail K. Naughton, CEO and Chairman of the Board of Histogen. “WealthForge’s platform and services will not only ensure our SEC compliance for these transactions, but will facilitate the investment process for our new shareholders.”
Wealthforge is said to be working closely with Gar Wood on this deal. Gar Wood Securities is a boutique, institutional broker-dealer. The firm is said to support a network of independent contractors that trade solely on an agency basis, and who have access to all major global markets covering equities and cash options.